Stockreport

Savara Announces Encore Presentations From the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) a...

Savara, Inc.  (SVRA) 
Last savara, inc. earnings: 3/12 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: savarapharma.com/investors/events-presentations
PDF LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical-stage biopharmaceutical company focused on rare respiratory diseases, announced [Read more]